Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | FDFT1 | P37268 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | UBE2I | P63279 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.33 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.33 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8118721 | 1.00 | MDM2 (0.37) | MDM2TP53MCL1FDFT1ALDH1A1 | |
| SCHEMBL8102100 | 0.89 | FDFT1 (0.41) | MDM2TP53FDFT1POLB | |
| SCHEMBL4108650 | 0.89 | FDFT1 (0.41) | MDM2TP53FDFT1POLB | |
| SCHEMBL4105250 | 0.89 | FDFT1 (0.44) | MDM2TP53FDFT1ALDH1A1POLB | |
| SCHEMBL8102958 | 0.89 | FDFT1 (0.44) | MDM2TP53FDFT1ALDH1A1POLB | |
| SCHEMBL8110962 | 0.88 | FDFT1 (0.38) | MDM2TP53MCL1FDFT1ALDH1A1 | |
| SCHEMBL4104304 | 0.88 | FDFT1 (0.38) | MDM2TP53MCL1FDFT1ALDH1A1 | |
| SCHEMBL4108524 | 0.87 | FDFT1 (0.41) | FDFT1KDM4EHPGDCCR4CCKBR | |
| SCHEMBL8112140 | 0.87 | FDFT1 (0.41) | FDFT1KDM4EHPGDCCR4CCKBR | |
| SCHEMBL8117935 | 0.86 | MDM2 (0.39) | MDM2TP53MCL1FDFT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1889632-A1 | REMEDY FOR XANTHOMA | National University Corp. Kobe University (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | SUGIYAMA YASUO | 2006-10-26 | — | — | US | disclosed |
| US-20060052362-A1 | Skeletal muscle protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1600166-A1 | SKELETAL MUSCLE PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1407782-A1 | PREVENTIVES/REMEDIES FOR ORGAN FUNCTIONAL DISORDERS AND ORGAN DYSFUNCTION | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1332763-A1 | HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL ELEVATING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-5885979-A | SQUALENE SYNTHETASE INHIBITOR TREATING OR PREVENTING HYPERLIPIDEMIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0705607-A2 | Condensed seven- or eight-membered heterocyclic compounds useful as antihypertriglyceridemic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082333-A1 | REMEDY FOR XANTHOMA | FDFT1, LSS, SQLE | MDM2 4751/4885TP53 3989/4885MCL1 3896/4885 |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | MDM2 4207/4885TP53 4413/4885MCL1 4640/4885 |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | MDM2 3842/4885TP53 3939/4885MCL1 4738/4885 |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | MDM2 4787/4885TP53 4873/4885MCL1 4442/4885 |
| US-20090118255-A1 | Crp Lowering Agent | SPR, RBP1, HMGCR | MDM2 4605/4885TP53 2438/4885MCL1 3485/4885 |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | HMGCR, LIPC, LIPA | MDM2 4722/4885TP53 4872/4885MCL1 4067/4885 |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | SQLE, DHPS, COASY | MDM2 4493/4885TP53 4757/4885MCL1 3771/4885 |
| US-20060052362-A1 | Skeletal muscle protecting agent | GYS1, CPT1B, TNNC1 | MDM2 4220/4885TP53 4734/4885MCL1 3845/4885 |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | MDM2 4207/4885TP53 4413/4885MCL1 4640/4885 |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | MDM2 4787/4885TP53 4873/4885MCL1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.